New Pre-Clinical Studies Demonstrate Cord Blood Stem Cells (CB-SC) Ameliorate the Graft-vs-Host Disease (GvHD) Involved in the Allogeneic Hematopoietic Stem Cell Transplantation

We are pleased to announce that Dr. Yong Zhao collaborated with his colleagues Dr. Robert Korngold’s group at the Center For Discovery and Innovation (CDI) of Hackensack Meridian Health,  published a new manuscript in Transplantation and Cellular Therapy, (the official journal of the American Society for Transplantation and Cellular Therapy), titled “Cord Blood Derived-Multipotent Stem Cells Ameliorate In-Vitro/In-Vivo Alloreactive Responses and this Effect is Associated with Exosomal Microvesicles in Vitro”.

Animal studies demonstrated that CB-SC ameliorated the development of GvHD responses in a xenogeneic human peripheral blood mononuclear cells (PBMC)-induced NSG mouse model. These results indicate that CB-SC can directly and indirectly attenuate alloreactive CD4 T cell activation and proliferation in vitro with a potentially related exosomal microvesicles (EV) mode of action and may have potential utilization as a cell therapy to control donor T cell mediated GvHD responses in vivo.